Key Highlights

  • CareDx shares closed at $61.37 today, up 13.00%, near 52-week highs.
  • CMS finalized 2027 Medicare clinical lab fee schedule changes that analysts view as favorable for CareDx's transplant diagnostics reimbursement outlook.
  • One research firm reiterated a Buy rating and raised its price target to $74 from $60, citing improved visibility into the company's reimbursement environment.
  • The move comes in contrast with peers like BillionToOne, which face more mixed reimbursement impacts from the same rule changes.

Favorable Medicare Fee Schedule Changes Drive Shares Higher

CareDx (NASDAQ:CDNA) shares surged today after the Centers for Medicare and Medicaid Services finalized 2027 clinical lab fee schedule changes that align rates with private payors, a shift analysts view as favorable for CareDx's transplant diagnostics reimbursement outlook. The reaction stands in contrast to peers such as BillionToOne (NASDAQ:BLLN), where the same rule changes have produced more mixed reimbursement impacts across different testing categories.

Analyst Reaction Reinforces the Bullish Case

Reinforcing the bullish reaction, one research firm's analyst reiterated a Buy rating and raised the price target to $74 from $60, citing improved visibility into the company's reimbursement environment following the CMS decision. The move comes as CareDx continues to streamline its portfolio, following its June 2026 sale of its Lab Solutions Business to a France-based diagnostics company, sharpening its focus on core transplant diagnostics.

The Leading Provider of Transplant Diagnostics

CareDx, known as "The Transplant Company," is a precision medicine company headquartered in Brisbane, California, focused on clinically differentiated healthcare solutions for transplant patients and their caregivers. Its comprehensive portfolio spans non-invasive molecular testing services, including AlloSure Kidney, AlloSure Heart, AlloSure Lung and AlloMap Heart, alongside HLA typing products and digital health platforms that support patients across the entire pre- and post-transplant journey.